AMT has developed Glybera as a gene therapy for patients with this disease.

AMT inks agreement with Progenika Biopharma for advancement of LPLchip Amsterdam Molecular Therapeutics and Progenika Biopharma announced today that the firms have entered right into a development and commercialization agreement for LPLchip, a diagnostic device to rapidly diagnose individuals with complete and partial lipoprotein lipase insufficiency http://clomidhelp.com/ . AMT has developed Glybera as a gene therapy for patients with this disease. In June of this year AMT announced new clinical data showing a one-time administration of its business lead product Glybera results in significant long-term health advantages for LPLD sufferers.

AMT Obtains Orphan Drug Designation for Its LPL Gene Therapy Product AMT today announced that its adeno-associated viral vector expressing lipoprotein lipase product has been designated while an orphan medicinal item for the treatment of LPL deficiency by the European Commission. This decision comes after a positive suggestion by the European Agency for the Evaluation of Medicinal Items. The designation confers regulatory support for accelerated development and a decade of market exclusivity after granting of marketing authorization. LPL deficiency is an ideal target for gene therapy and our preclinical data provide us great confidence that we may be able to rapidly give a treatment in this area of unmet medical need, stated Dr.